BPN14770 在健康受试者中进行的 1 期单剂量递增临床试验-猫眼课题宝

BPN14770 在健康受试者中进行的 1 期单剂量递增临床试验

批准号：

9077367

负责人：

Mark E Gurney

金额：

$69.47万

依托单位：

TETRA DISCOVERY PARTNERS, INC.

依托单位国家：

美国

项目类别：

财政年份：

2015

资助国家：

美国

项目状态：

已结题

起止时间：

2015-09-01 至 2016-05-31

来源：

https://reporter.nih.gov/project-details/9077367

关键词：

Activities of Daily Living Address Adult Affect Aftercare Alzheimer&apos s Disease Amyloid beta-Protein Aricept Binding Biochemical Biological Assay Biological Availability Biological Markers Boxing Brain Brain Part CREB1 gene Central Nervous System Diseases Cholinesterase Inhibitors Clinical Clinical Trials Clinical dementia rating scale Cocrystallography Cognition Cognitive Collaborations Cyclic AMP-Dependent Protein Kinases Cytochrome P450 Dementia Demographic Aging Dendritic Spines Deposition Developed Countries Diagnostic Dimensions Dose Drug Targeting Elderly Enrollment Functional disorder Funding Generations Goals Health Hepatocyte Hippocampus (Brain)Human Impaired cognition In Vitro Individual Knowledge Lead Life Long-Term Potentiation Measures Medical Memory Mental Depression Metabolic Activation Metabolism Modeling Monkeys Morphology National Institute on Aging Oral Outcome Paired-Associate Learning Pathology Pathway interactions Patients Peptides Persons Pharmaceutical Preparations Phase Phase III Clinical Trials Plasma Population Prevention Property Publishing Recommendation Retrieval Rodent Rolipram Sales Senile Plaques Short-Term Memory Solubility Structure Sum System Therapeutic Toxic effect United States National Institutes of Health Vomiting base cerebral atrophy clinical research site clinically significant cognitive function cognitive testing cooperative study coping design drug market experience genotoxicity impression improved in vivo inhibitor/antagonist instrument member mental state mild cognitive impairment mouse model neurochemistry neuroimaging neuron loss phase III trial phosphodiesterase 4D phosphoric diester hydrolase pre-clinical programs scaffold screening synaptic function working group

项目摘要

项目成果

Mark E Gurney的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is an increasing medical burden due to the aging demographics of the US population. The most common form of dementia among older adults, AD affects parts of the brain important for memory formation and retrieval, seriously impairing a person's ability to live independently and cope with daily activities. In collaboration with the NIH Blueprint Neurotherapeutics Program, we seek to develop phosphodiesterase Type 4 (PDE4) allosteric modulators for improving cognition in accordance with the Target Product Profile below. Ideally, the therapeutic will improve cognition in MCI patients and impact AD pathophysiology, thereby slowing conversion to probable AD. Drug PropertiesMinimum Acceptable ResultIdeal ResultPrimary Drug IndicationImprovement of cognition in persons with Mild Cognitive Impairment (MCI) due to probable ADSlowing of conversion from MCI to probable ADPatient PopulationPatients with MCI due to probable AD according to the NIAA/AA working group criteriaPatients with MCI due to probable AD according to the NIAA/AA working group criteriaDelivery ModeOralOralTreatment DurationChronicChronicRegimenOral, once dailyOral, once daily

期刊论文(0)

专著(0)

科研奖励(0)

会议论文